cas 3618-03-9|| where to buy methyl cis-4-hydroxycyclohexanecarboxylate

Produktname:methyl cis-4-hydroxycyclohexanecarboxylate

IUPAC Name:methyl (1s,4s)-4-hydroxycyclohexane-1-carboxylate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM104761-25g	in stock	ƴŽ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3618-03-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3618-03-9; Molekulare Formel:C8H14O3; Schmelzpunkt:-; SMILES-Code:COC(=O)[C@@H]1CC[C@H](O)CC1; Dichte:

: Katalognummer:CM104761; Molekulargewicht:158.2; Siedepunkt:; Mdl-Nr.:MFCD20441962; Lagerung:

: Cyclohexanes; Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.

: Cyclanes; Cyclanes are secondary metabolites that can be found in plants, and are also biochemicals that can be used in medicine. Cyclanes are found in pine trees, and are used in the making of plastics. Cyclenes are found in cinnamon, and have antifungal properties.

: KT-474; Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.